National Institute of Mental Health

The National Institute of Mental Health is presented in this account through its former director, Tom Insel, rather than through a formal institutional statement. At a psychedelic psychiatry conference, Insel’s participation placed a former head of the national mental-health agency alongside senior psychiatric figures in a discussion of psychedelic-assisted therapy. His remarks conveyed both the treatment’s promise and the risks of mishandling its return to public and clinical life.

Institutional Presence

At the conference’s plenary panel, “Future of Psychedelic Psychiatry,” Insel appeared with Paul Summergrad, former head of the American Psychiatric Association. The panel was organized and moderated by George Goldsmith, who, with Ekaterina Malievskaia, had devoted resources to winning approval for psilocybin-assisted therapy in the European Union. Their presence at a psychedelic convention mattered: to the standing-room audience, the two former institutional leaders signaled that psychedelic therapy was gaining recognition within the mental-health establishment.

Insel’s Assessment of Psychedelic Therapy

Insel connected the treatment’s promise to a broader criticism of mental-health care, arguing that its record compared poorly with the achievements of other branches of medicine. He noted that care had not lowered mortality from serious psychiatric disorders and pointed to psychedelic therapy as a promising new model. He also singled out the combined approach—not simply administering a drug, but providing “psychedelic-assisted psychotherapy”—as novel. His qualification was institutional as well as clinical: regulators accustomed to assessing drugs in isolation might find this model difficult to evaluate.

Caution and the Limits of Representation

When Goldsmith asked what advice Insel would give researchers working to bring psychedelic therapy to patients, Insel replied, “Don’t screw it up!” He elaborated that promise could be lost through failures of safety, scientific rigor, or reputation. He also urged researchers to avoid associations with recreational use and warned that one careless researcher or one patient’s disastrous experience could damage prospects for the field as a whole. These were Insel’s cautions as a former agency head speaking on a conference panel; the account does not present them as an official National Institute of Mental Health policy.

The panel’s exchange captures the tension surrounding institutional acceptance: psychedelic therapy drew interest partly because it departed from familiar models, yet that same novelty made careful evaluation and public trust essential. The National Institute of Mental Health’s role in this episode is therefore indirect but consequential, embodied in the appearance and judgment of its former leader at a moment when the treatment was moving toward renewed legitimacy.